Insider trading

Period: 120 months Stock: NKTR + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

338 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

338 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

338 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

338 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
338 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
338 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

338 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
16 May 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$62.15K 3,179 at 19.55
4.6%
16 May 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$61.50K 3,146 at 19.55
1.7%
16 May 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$57.85K 2,959 at 19.55
4.6%
16 May 2017
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$51.83K 2,651 at 19.55
4.8%
16 May 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$33.25K 1,701 at 19.55
4.9%
16 May 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$28.35K 1,450 at 19.55
3.2%
15 May 2017
CHESS ROBERT Director
Sold, plan not stated
$98.95K 5,000 at 19.79
1.8%
17 Apr 2017
CHESS ROBERT Director
Sold, plan not stated
$93.60K 5,000 at 18.72
1.8%
7 Apr 2017
Lingnau Lutz Director
Sold, plan not stated
$140.35K 7,000 at 20.05
23.0%
5 Apr 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$3.91M 180,000 at 21.70
73.9%
Sold half or more
5 Apr 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$2.17M 100,000 at 21.70
74.3%
Sold half or more
5 Apr 2017
Sold, plan not stated
$328.20K 15,000 at 21.88
29.7%
20 Mar 2017
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$2.22M 112,500 at 19.69
66.9%
Sold half or more
14 Mar 2017
CHESS ROBERT Director
Sold, plan not stated
$77.05K 5,000 at 15.41
1.8%
3 Mar 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated 2×
$494.23K 32,494 at 15.21
31.9%
2 Mar 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$2.54M 167,506 at 15.15
70.7%
Sold half or more
21 Feb 2017
Lingnau Lutz Director
Sold, plan not stated
$392.40K 30,000 at 13.08
49.6%
16 Feb 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$113.48K 8,636 at 13.14
4.9%
16 Feb 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$42.53K 3,237 at 13.14
1.7%
16 Feb 2017
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$31.00K 2,359 at 13.14
3.3%
16 Feb 2017
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$28.84K 2,195 at 13.14
3.3%
16 Feb 2017
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$25.82K 1,965 at 13.14
3.4%
16 Feb 2017
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$19.14K 1,457 at 13.14
3.1%
16 Feb 2017
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$16.57K 1,261 at 13.14
3.5%
8 Feb 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.14M 87,500 at 13.04
33.0%
3 Feb 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$106.14K 8,505 at 12.48
5.7%
2 Feb 2017
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$823.21K 66,495 at 12.38
32.2%
17 Jan 2017
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.08M 87,500 at 12.35
33.0%
7 Dec 2016
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.07M 87,500 at 12.24
41.6%
17 Nov 2016
ROBIN HOWARD W President & CEO
Sold, plan not stated
$1.21M 87,500 at 13.87
41.6%
16 Nov 2016
ROBIN HOWARD W President & CEO
Sold, plan not stated
$83.17K 5,958 at 13.96
4.6%
16 Nov 2016
Thomsen Jillian B. SVP & Chief Accounting Officer
Sold, plan not stated
$27.72K 1,986 at 13.96
4.5%
16 Nov 2016
Nicholson John SVP & Chief Operating Officer
Sold, plan not stated
$23.09K 1,654 at 13.96
1.4%
16 Nov 2016
Labrucherie Gil M SVP & Chief Financial Officer
Sold, plan not stated
$23.09K 1,654 at 13.96
3.1%
16 Nov 2016
Hora Maninder SVP Pharma Dev & Mfg Ops
Sold, plan not stated
$23.09K 1,654 at 13.96
3.2%
16 Nov 2016
Gergel Ivan P. SVP & Chief Medical Officer
Sold, plan not stated
$11.84K 848 at 13.96
3.1%
16 Nov 2016
Doberstein Stephen K SVP & Chief Scientific Officer
Sold, plan not stated
$9.35K 670 at 13.96
3.5%
24 Oct 2016
GREER R SCOTT Director
Bought
$202.50K 15,000 at 13.50
14.1%
First buy on file
Showing 301–338 of 338. ← Newer Page 7 of 7